Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. Vertex Pharmaceuticals beat analysts’ revenue ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

There's more good news than bad news for this big biotech stock. Were Vertex's Q2 results horrible? Not at all. Instead, investors reacted negatively after the big biotech company announced two ...

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting a separate impairment charge of $379 million tied to an earlier ...

Vertex Solutions has been awarded a contract to deliver 25 T-38 Gen 2 enhanced immersive training devices (eITDs) to the U.S. Air Force, aimed at enhancing pilot training for fighter and bomber ...

In today’s rapidly evolving AI landscape, enterprises need reliable platforms that combine powerful models with practical deployment capabilities. Google Cloud’s latest enhancements to Vertex AI and ...